Bio-Techne Corp Files 8-K on Operations and Financials
Ticker: TECH · Form: 8-K · Filed: May 1, 2024 · CIK: 842023
| Field | Detail |
|---|---|
| Company | Bio-Techne Corp (TECH) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, sec-filing
TL;DR
Bio-Techne dropped an 8-K, check it for the latest on their financials and operations.
AI Summary
Bio-Techne Corporation filed an 8-K on May 1, 2024, reporting on its results of operations, other events, and financial statements. The filing details the company's financial condition and any significant occurrences that have transpired. Specific financial figures and operational updates are expected to be detailed within the accompanying exhibits.
Why It Matters
This 8-K filing provides investors with crucial, up-to-date information on Bio-Techne's financial performance and significant business events, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for reporting operational and financial information, not indicating any immediate or unusual risks.
Key Players & Entities
- BIO-TECHNE Corporation (company) — Registrant
- May 1, 2024 (date) — Date of earliest event reported
- Minnesota (location) — State of Incorporation
- 614 McKinley Place NE (address) — Principal Executive Offices
- Minneapolis (location) — City of Principal Executive Offices
- 55413 (zip_code) — Zip Code of Principal Executive Offices
- 612-379-8854 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates 'Results of Operations and Financial Condition' as an item, suggesting financial performance data is included, though specific figures are detailed in accompanying exhibits.
What 'Other Events' are being disclosed by Bio-Techne Corporation?
The 8-K lists 'Other Events' as a reporting item, implying significant business occurrences are detailed within the filing's exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 1, 2024.
What is Bio-Techne Corporation's principal executive office address?
Bio-Techne Corporation's principal executive offices are located at 614 McKinley Place NE, Minneapolis, Minnesota 55413.
What is the Commission File Number for Bio-Techne Corporation?
Bio-Techne Corporation's Commission File Number is 0-17272.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-05-01 06:30:13
Filing Documents
- tmb-20240501x8k.htm (8-K) — 35KB
- tmb-20240501xex99d1.htm (EX-99.1) — 583KB
- tmb-20240501xex99d2.htm (EX-99.2) — 21KB
- 0001558370-24-006319.txt ( ) — 793KB
- tmb-20240501.xsd (EX-101.SCH) — 3KB
- tmb-20240501_lab.xml (EX-101.LAB) — 15KB
- tmb-20240501_pre.xml (EX-101.PRE) — 11KB
- tmb-20240501x8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on May 1, 2024, describing the results of operations for the quarter ended March 31, 2024, and its financial condition as of March 31, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on May 1, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release, dated May 1, 2024, announcing results of operations 99.2 Press Release, dated May 1, 2024, announcing cash dividend 104 - Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNE CORPORATION Date: May 1, 2024 By: /s/ Shane V. Bohnen Shane V. Bohnen Senior Vice President, General Counsel and Secretary